<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523690</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00072940</org_study_id>
    <secondary_id>UL1TR001079</secondary_id>
    <nct_id>NCT02523690</nct_id>
  </id_info>
  <brief_title>Evaluating Muscle Weakness Improvement With Lorcaserin in ICU</brief_title>
  <acronym>EMILI</acronym>
  <official_title>Evaluating Lorcaserin Drug Therapy For ICU-Acquired Weakness: A Pilot Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ICU acquired muscle weakness is a significant problem in patients recovering from critical
      illness. This trial will evaluate the safety and efficacy of a drug in improving muscle
      weakness in critically ill patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment of eligible patients
  </why_stopped>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Handgrip Strength as Measured by Hand Dynamometer</measure>
    <time_frame>Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
    <description>Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Handgrip Strength as Measured by Hand Dynamometer</measure>
    <time_frame>Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
    <description>Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score</measure>
    <time_frame>Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
    <description>Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 [no visible or noticeable contraction] to 5 [maximum strength] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score</measure>
    <time_frame>Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
    <description>Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 [no visible or noticeable contraction] to 5 [maximum strength] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quadriceps Strength as Measured by Handheld Dynamometer</measure>
    <time_frame>Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
    <description>Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quadriceps Strength as Measured by Handheld Dynamometer</measure>
    <time_frame>Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
    <description>Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Muscle Weakness</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old

          -  Sepsis [ ≥2 Systemic Inflammatory Response Syndrome (SIRS) Criteria AND known or
             suspected infection]

          -  Muscle weakness [Medical Research Council sum score &lt;48/60 or handgrip strength &lt;11 kg
             in men and &lt;7 kg in women]

          -  Obey Commands [Score for DeJonghe Awakening Score of ≥3/5]

        Exclusion Criteria:

          -  Severe renal insufficiency [Creatinine Clearance &lt;30 mL/min - or receiving dialysis]

          -  Acute infectious or auto-immune hepatitis, acute liver failure or a history of
             cirrhosis without liver transplant

          -  History of psychosis

          -  Bradycardia, or 2nd or 3rd degree Atrio-Ventricular block without pacemaker

          -  History of valvular heart disease without valve replacement

          -  History of priapism

          -  Pre-existing cognitive impairment

          -  Receiving drugs with serotonergic effects and/or CYP2D6 substrates which cannot be
             substituted stopped or titrated.

          -  Receiving Sulfonylurea medication at the time of the study

          -  Prior neuromuscular or central nervous system disease, including pre-existing
             neuropathy

          -  Inability to perform study's muscle strength assessments based on patient's baseline
             status prior to hospital admission

          -  Unable to receive, or unlikely to absorb study drug (e.g. bowel obstruction, ischemia,
             or infarction; short gut syndrome)

          -  Body mass index &gt;40

          -  Patient not expected to survive &gt;4 days

          -  Pregnancy or lactation

          -  Allergy to lorcaserin or lorcaserin taken in the prior 7 days

          -  Enrolled in another interventional drug or physical rehabilitation trial

          -  Physician declines for patient to be enrolled

          -  Patient or proxy declines consent

          -  Unable to reach proxy for consent

          -  Non-English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale M Needham, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <results_first_submitted>December 26, 2019</results_first_submitted>
  <results_first_submitted_qc>December 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02523690/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="19.8"/>
                    <measurement group_id="B2" value="56.0" spread="18.4"/>
                    <measurement group_id="B3" value="60.6" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Handgrip Strength as Measured by Hand Dynamometer</title>
        <description>Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better)</description>
        <time_frame>Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Handgrip Strength as Measured by Hand Dynamometer</title>
          <description>Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better)</description>
          <units>percent of predicted strength</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="2.93"/>
                    <measurement group_id="O2" value="1.75" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Handgrip Strength as Measured by Hand Dynamometer</title>
        <description>Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better)</description>
        <time_frame>Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Handgrip Strength as Measured by Hand Dynamometer</title>
          <description>Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better)</description>
          <units>percent of predicted strength</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" spread="1.89"/>
                    <measurement group_id="O2" value="2.25" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score</title>
        <description>Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 [no visible or noticeable contraction] to 5 [maximum strength] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better).</description>
        <time_frame>Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score</title>
          <description>Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 [no visible or noticeable contraction] to 5 [maximum strength] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="3.5"/>
                    <measurement group_id="O2" value="3.50" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score</title>
        <description>Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 [no visible or noticeable contraction] to 5 [maximum strength] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better).</description>
        <time_frame>Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score</title>
          <description>Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 [no visible or noticeable contraction] to 5 [maximum strength] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.73"/>
                    <measurement group_id="O2" value="0.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quadriceps Strength as Measured by Handheld Dynamometer</title>
        <description>Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle.</description>
        <time_frame>Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quadriceps Strength as Measured by Handheld Dynamometer</title>
          <description>Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="1.83"/>
                    <measurement group_id="O2" value="4.15" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quadriceps Strength as Measured by Handheld Dynamometer</title>
        <description>Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle.</description>
        <time_frame>Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quadriceps Strength as Measured by Handheld Dynamometer</title>
          <description>Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.23"/>
                    <measurement group_id="O2" value="2.13" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While admitted in hospital. For the 5 participants in this study, the mean number of days between enrollment and hospital discharge is 17.6 days (standard deviation 12.9 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
Lorcaserin: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
Placebo: Oral or enteral, single dose. Oral or enteral, single dose two days later</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="03"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dale Needham</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-287-3343</phone>
      <email>dale.needham@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

